ModifiedUnitedHealthcarePolicy CS107.AE

Rhinoplasty and Other Nasal Procedures

Clinical coverage criteria for rhinoplasty and other nasal procedures, defining when nasal valve repair, rhinophyma excision, rhinoplasty (primary, revision, tip), and related procedures are considered reconstructive and medically necessary for UnitedHealthcare members.

Policy Summary

PayerUnitedHealthcare

PolicyRhinoplasty and Other Nasal Procedures

Policy CodePolicy CS107.AE

Change TypeMaterial updates and code removalreferences updated

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of prior conservative therapy, symptom severity (NOSE or rTNSS), and photographs/modified Cottle maneuver findings when requesting coverage for nasal valve or related procedures.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate this Medical Policy does not apply to the states of Idaho and Kansas; refer to the state-specific policy versions.

Added language clarifying that benefit coverage is determined by federal, state, or contractual requirements and that medical records documentation may be required to assess clinical criteria but does not guarantee coverage.

Removed CPT code 30999 from Applicable Codes.

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

7distinct procedure categories

3procedures listed as unproven

Manycodes listed for reference

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

RCTs+RCTs / prospective studies cited

2states explicitly excluded

Coverage Criteria for Nasal Procedures

Nasal valve repair — medically necessary

Nasal valve procedures/repair of nasal vestibular stenosis or alar collapse are considered reconstructive and medically necessary when ALL of the following are present:

Nasal valve/vestibular stenosis criteria: Prolonged, persistent obstructed nasal breathing due to internal and/or External Nasal Valve compromise; and other causes of nasal obstruction (e.g., rhinosinusitis, allergic rhinitis, vasomotor rhinitis, nasal polyposis, adenoid hypertrophy, nasopharyngeal masses) have been adequately treated with maximal therapy and obstruction persists; and nasal septal deviation and turbinate hypertrophy are either not present, have been previously surgically treated, or are scheduled to be surgically treated at the same time as the nasal valve procedure; and documented visible collapse of the alar (lower lateral) cartilage and/or lateral nasal wall with deep inspiration; and documented subjective and audible improvement in nasal airflow during modified Cottle maneuver; and photographs clearly document dynamic collapse or anatomic deformities narrowing the internal and/or External Nasal Valve consistent with the clinical exam; and the surgeon has clearly described whether the compromise is static or dynamic, whether internal and/or external valve is involved, and a clear surgical plan including need for cartilage graftall conditions required

From policy instructions for use

Rhinophyma excision — medically necessary

Rhinophyma excision is considered reconstructive and medically necessary when ALL of the following are present:

Rhinophyma criteria: One of the following: prolonged, persistent obstructed nasal breathing due to rhinophyma; or chronic infection or bleeding unresponsive to medical management due to rhinophyma; and photographs clearly document rhinophyma as the primary cause of an anatomic Mechanical Nasal Airway Obstruction or chronic infection consistent with the clinical exam; and the proposed procedure is designed to correct the anatomic obstruction or address the chronic infectionall conditions required

From policy instructions for use

Rhinoplasty for congenital anomalies — medically necessary

Rhinoplasty for congenital anomalies is considered reconstructive and medically necessary when the following is present:

Congenital rhinoplasty: Rhinoplasty is performed for a nasal deformity associated with congenital craniofacial anomalies (examples include Pierre Robin, Apert, Fraser, Binder, Goldenhar syndromes, nasal dermoids, Tessier nasal cleft, or associated with cleft lip or cleft palate)all conditions required

Single-item criterion from policy

Rhinoplasty-primary — medically necessary

Rhinoplasty-primary is considered reconstructive and medically necessary when ALL of the following are present:

Primary rhinoplasty: Indication is one of: prolonged, persistent obstructed nasal breathing due to nasal bone and septal deviation as the primary causes of an anatomic Mechanical Nasal Airway Obstruction; nasal fracture with bone displacement severe enough to cause obstruction; or residual large cutaneous defect after malignancy/trauma; and the nasal airway obstruction cannot be corrected by septoplasty alone as documented in the medical record; and photographs clearly document the nasal bone/septal deviation as the primary cause consistent with exam; and the proposed procedure is designed to correct the anatomic obstruction by centralizing the nasal bony pyramid and straightening the septum; and nasal airway obstruction is causing significant symptoms; and obstructive symptoms persist despite conservative management for 4 weeks or greater (including nasal steroids or immunotherapy where appropriate)all conditions required

Policy-specified primary rhinoplasty criteria

Rhinoplasty-revision — medically necessary when complication causes persistent functional impairment

Rhinoplasty-revision is considered reconstructive and medically necessary when ALL of the following are present:

Revision rhinoplasty: Required as treatment of a complication or residual deformity from prior primary surgery that was performed to address a Functional Impairment when a documented Functional Impairment persists due to the complication/deformity; and photographs clearly document the secondary deformity/complication as the primary cause of an anatomic Mechanical Nasal Airway Obstruction consistent with the clinical exam; and the proposed procedure is designed to correct the anatomic obstruction and relieve the airway obstruction by correcting the deformity or treating the complication; and nasal airway obstruction is causing significant symptoms; and obstructive symptoms persist despite conservative management for 4 weeks or greater (including nasal steroids or immunotherapy where appropriate)all conditions required

Revision rhinoplasty considered reconstructive when treating persistent functional impairment from complication

Rhinoplasty-tip — medically necessary

Rhinoplasty-tip is considered reconstructive and medically necessary when ALL of the following are present:

Tip rhinoplasty: Prolonged, persistent obstructed nasal breathing due to tip drop that is the primary cause of an anatomic Mechanical Nasal Airway Obstruction; and photographs clearly document tip drop as the primary cause consistent with the clinical exam; and the proposed procedure is designed to lift the nasal tip and relieve the obstruction; and nasal airway obstruction is causing significant symptoms; and obstructive symptoms persist despite conservative management for 4 weeks or greater (including nasal steroids or immunotherapy where appropriate)all conditions required

Tip rhinoplasty criteria from policy

Nasal polypectomy — conditional

Nasal polypectomy is considered reconstructive and medically necessary in certain circumstances; see referenced criteria:

Nasal polypectomy: Coverage and medical necessity are determined using the InterQual ® Procedures, Polypectomy, Nasal clinical criteria referenced by this policy; nasal polypectomy is considered reconstructive and medically necessary only when InterQual criteria are metsee InterQual

Policy defers to InterQual criteria for clinical specifics

Covered with criteria / Conditional coverage elements

Coverage considerations implied by evidence and guideline statements (extract of evidence-based criteria):

General coverage considerations for nasal valve/functional rhinoplasty: Surgery is considered when objective and subjective assessments demonstrate clinically significant nasal obstruction and appropriate patient selection supports improvement; adjunctive correction of other anatomic contributors (septum, turbinates) is often required to optimize outcomesclinical judgment per guideline

Supported by AAO-HNS statement and systematic reviews

Timing considerations for cleft-related rhinoplasty: Definitive rhinoplasty generally recommended after completion of facial growth; intermediate intervention may be considered for severe obstruction or significant psychosocial distressper ACPA guidance

ACPA guidance summarized

Absorbable nasal implant consideration:

Absorbable nasal cartilage support implants

Evidence-supported conditions and typical study eligibility/outcomes for bioabsorbable lateral wall implants:

Bioabsorbable implant evidence context: Study populations typically included symptomatic patients with nasal valve collapse or lateral wall insufficiency (often severe NOSE scores); trials and series reported short- to mid-term improvements (3–12 months, and some follow-up to 24 months) in NOSE and VAS scores versus baseline or sham; adverse events were generally low (approx. 5%) and typically mild-to-moderatestudy-based

Randomized and prospective case series evidence summarized

Nasal Septal Swell Body Reduction

Evidence and limitations for Nasal Septal Swell Body (NSB) reduction procedures:

NSB reduction interventions: Interventions including RFA, coblation, microdebridement, and TCRF have shown symptom improvements in small prospective and retrospective studies; one randomized trial suggested benefit of combined SBVR + turbinoplasty vs turbinoplasty alone at 3 months; however most studies are small, short-term, and heterogeneousstudy-based

Long-term benefits not established

Posterior Nasal Nerve / Sphenopalatine Ganglion Ablation

Evidence and typical patient selection for PNN/SPG ablation procedures:

PNN/SPG ablation evidence context: RCTs and prospective studies enrolled adults with chronic rhinitis (commonly ≥6 months), predefined minimum rTNSS thresholds, and prior failure of medical therapy; studies (cryoablation, temperature-controlled RF neurolysis) demonstrated clinically meaningful reductions in rTNSS and improved quality-of-life measures sustained to 12–24 months in many participants, though limitations include heterogeneous rhinitis types, variable medication management, and limited sustained control armsstudy-based

Trial eligibility and outcomes summarized

Candidate selection (trial-derived)

Evidence-based coverage considerations (summary of trial eligibility elements used in RCTs and prospective studies):

Primary candidate criteria: Patient has chronic rhinitis symptoms for at least the minimum durations used in trials (commonly ≥4–6 months) AND documented baseline symptom severity meeting trial thresholds (eg, rTNSS ≥4 or ≥6 with minimum subscores for rhinorrhea/congestion) AND inadequate response to prior medical therapy (eg, intranasal steroids for ≥4 weeks)see text

Trial-derived candidate selection

Responder/outcome criteria

Outcome / responder definition used across RCTs and studies:

Responder definition: Responder defined as ≥30% reduction in rTNSS from baseline (or equivalent meaningful improvement on validated outcome measures such as NOSE or RQLQ)≥30% rTNSS reduction

Used as primary endpoint in multiple RCTs

Evidence summary supporting symptomatic improvement with TCRF

Clinical evidence from randomized and observational studies shows short‑ and up to two‑year improvements for temperature‑controlled radiofrequency (TCRF) in selected patients with nasal valve collapse when assessed with NOSE score.

TCRF demonstrated outcomes: Randomized trial (Silvers 2021) demonstrated higher 3‑month responder rate for active TCRF vs sham with substantial NOSE score reduction; observational and cohort studies report sustained improvements to 12–24 months with approximately 90% responder rates in treated cohorts and large mean NOSE reductions at two yearsstudy-based

RCT and multiple follow-up/cohort studies summarized

Evidence limitations and need for comparative studies

Quality and comparative evidence limitations:

Evidence limitations: Systematic reviews and evidence assessments note small study sizes, moderate-to-high risk of bias, industry sponsorship in several trials, limited comparative data, and lack of long‑term randomized comparisons; these limitations may affect determinations of comparative effectiveness and long-term benefit

ECRI, Hayes, and systematic reviews summarized

Each reconstructive indication in this policy is limited to the specific clinical criteria listed for that procedure. Stated differently, a procedure described as reconstructive and medically necessary in this policy is not considered reconstructive and medically necessary in all other indications. For example, nasal valve repair, rhinophyma excision, primary and revision rhinoplasty, and tip rhinoplasty are covered only when the explicit criteria (such as documented anatomic cause, photographic documentation, documented failure of conservative management, and the specified surgical plan) are met; procedures performed outside those specified criteria are excluded.

The policy lists specific procedures considered unproven and not medically necessary because of insufficient evidence of safety and/or efficacy, including: absorbable polylactic acid nasal cartilage support implants (for example, the Latera Absorbable Nasal Implant), nasal septal swell body (NSB) reduction when used for nasal obstruction, posterior nasal nerve or sphenopalatine ganglion ablation by any method (including cryoablation devices such as RhinAer or ClariFix), and radiofrequency treatment of nasal valves (for example, the VivAer ARC Stylus).

Certain techniques and procedures are noted to have insufficient evidence of long-term benefit or carry uncertainty regarding technique selection. The document highlights that many surgical approaches to nasal valve and related procedures reflect uncertainty in choosing the optimal technique and that well‑designed, adequately powered randomized trials of single techniques are needed. NSB reduction methods (RFA, coblation, microdebridement, submucosal reduction) and other small, heterogeneous studies demonstrate short‑term symptom improvement but have limited long‑term data and methodological limitations, so selection of these techniques without patient‑specific justification is not well supported.

The American Academy of Otolaryngology–Head and Neck Surgery (AAO‑HNS) indicates that FDA‑approved biomaterials may be used in sinonasal procedures at the treating physician’s discretion, considering available evidence and surgeon experience. However, the AAO‑HNS position and the policy text do not specifically address non–steroid‑releasing absorbable nasal implants (such as Latera). Evidence reviews (e.g., Hayes) emphasize that studies of absorbable implants are generally low quality and lack adequate control groups, so the policy limits implant use to circumstances with documented rationale and informed discussion of limited long‑term comparative evidence.

The policy identifies comparative‑effectiveness gaps for cryoablation devices and other posterior‑nasal‑nerve neurolysis technologies (ClariFix, RhinAer) and for intranasal radiofrequency devices (VivAer) — specifically noting that published studies generally do not compare these devices directly with alternative active treatments. Evidence reviews conclude that current data do not permit determination of whether outcomes with ClariFix or RhinAer are better, worse, or similar to other medical or surgical options.

Independent evidence assessments (ECRI, Hayes) characterize the quality of available studies for several nasal devices and procedures as low to very‑low, with small sample sizes, single‑group designs, industry sponsorship in some trials, and limited comparative data. The policy segment does not list additional explicit exclusions beyond those described, but these evidence assessments inform the policy’s cautious stance and potential noncoverage when trial‑derived eligibility and prior‑therapy requirements are not documented.

This Medical Policy does not apply to the states of Idaho and Kansas. For members in those states, refer to the applicable state‑specific policy versions and applicable federal, state, or contractual requirements when determining coverage.

Examples of technologies considered unproven or not medically necessary summarized in the policy include bioabsorbable lateral wall implants (e.g., Latera), septal swell body (NSB) reduction techniques (including RFA, coblation, microdebridement), and posterior nasal nerve/sphenopalatine ganglion ablation devices (e.g., RhinAer, ClariFix). The policy notes available studies often show short‑term symptom improvement but are limited by small size, heterogeneity, and lack of long‑term controlled data.

Use of absorbable nasal implants is addressed with caution: although short‑ to mid‑term symptom improvements have been reported, evidence reviews find study quality generally poor and note a lack of long‑term controlled comparisons. The policy therefore requires documentation of clinical justification and shared decision making when implants are considered, and it cautions that implant use based solely on limited, low‑quality evidence without comparative justification or appropriate follow‑up may be considered not medically necessary.

The policy highlights methodological limitations in studies supporting NSB reduction and some implant procedures: many studies are small, nonrandomized, single‑arm series, and have short follow‑up (commonly 3–12 months). These limitations restrict confidence in long‑term outcomes and inferences about comparative effectiveness, and they are cited as reasons for the policy’s conservative coverage positions for these interventions.

Evidence summaries from Hayes and ECRI describe overall concerns including small study sizes, risk of bias, industry involvement in some trials, lack of head‑to‑head comparisons, and limited long‑term follow‑up. These assessments characterize support for some devices as minimal or unclear and underscore the need for higher‑quality comparative trials to inform coverage decisions.

Hayes concluded there is only minimal support for the VivAer radiofrequency procedure based on the available studies (mostly single‑group pre/post designs with small samples), noting that the RCT showed short‑term benefit but overall evidence remains limited and longer‑term comparative data are lacking.

Applicable Codes and Coding Notes

Applicable CPT codes (part 1)CPT

30117	Excision or destruction (e.g., laser) of intranasal lesion; internal approach.
30120	Excision or surgical planing of skin of nose for rhinophyma.
30400	Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip.
30410	Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip.
30420	Rhinoplasty, primary; including major septal repair.
30430	Rhinoplasty, secondary; minor revision (small amount of nasal tip work).
30435	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies).
30450	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies).

Applicable CPT codes (part 2)CPT

30460	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip only.
30462	Rhinoplasty for nasal deformity secondary to congenital cleft lip and/or palate, including columellar lengthening; tip, septum, osteotomies.
30465	Repair of nasal vestibular stenosis (e.g., spreader grafting, lateral nasal wall reconstruction).
30468	Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s).
30469	Repair of nasal valve collapse with low energy, temperature-controlled (i.e., radiofrequency) subcutaneous/submucosal remodeling.
31237	Nasal/sinus endoscopy, surgical; with biopsy, polypectomy or debridement (separate procedure).
31242	Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve.
31243	Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve.
64999	Unlisted procedure, nervous system

Applicable HCPCSHCPCS

L8699

Prosthetic implant, not otherwise specified

No explicit codes in this excerptmixed

No codes listed

Procedures discussed (no explicit codes in excerpt)mixed

No codes listed

FDA product codes and 510(k) identifiers mentionedmixed

LRC	FDA product code: instrument, ENT, manual surgical (devices used for rhinoplasty and other sinus surgeries) - 510(k)-exempt
LYA	FDA product code for intranasal septal splint devices (Class I)
K200300	VivAer® Stylus 510(k) clearance (referenced FDA ID)
K161191	Latera Absorbable Nasal Implant 510(k) clearance (Stryker)
K190356	ClariFix Device 510(k) clearance (cryosurgical tool)
K221907	RhinAer Stylus 510(k) clearance (Aerin Medical) for posterior nasal nerve regions

Removed CPT CodesCPTNot Covered

30999

Unlisted procedure, nose (NOTE: removed from Applicable Codes in this revision)

Conservative management duration

Conservative therapy duration (rhinoplasty-primary/revision/tip)Obstructive symptoms must persist despite conservative management for 4 weeks or greater (including nasal steroids or immunotherapy where appropriate)

Conservative therapy duration (Prolonged, Persistent Nasal Airway Obstruction)Defined as failure to respond to six weeks of medical management (nasal steroids, antihistamines, decongestants)

Conservative measures examplesNasal corticosteroid sprays, antihistamines, decongestants, and completion of elimination of drug‑induced rhinitis (eg, Rhinitis Medicamentosa)

rTNSS responder definition

Responder definition (rTNSS)

Prior Authorization and Documentation Requirements

Prior Authorization

Prior authorization / coding review

Prior authorization and coding review may be required for nasal surgical procedures. All nasal surgical claims may be subject to coding review to determine whether the procedure is considered reconstructive (medically necessary) versus cosmetic. Providers should expect UnitedHealthcare to review submitted CPT/Codes and operative documentation to confirm indication and scope of repair.

Affected codes may include: 30117, 30120, 30400, 30410, 30420, 30430, 30435, 30450, 30460, 30462, 30465, 30468, 30469, 31237, 31242, 31243, 64999, L8699 (chunks 10–11)
Cosmetic vs reconstructive determination will drive coverage and reimbursement (chunks 10, 11)

Prior Authorization

Prior authorization recommended for nasal valve procedures and implants

UnitedHealthcare recommends prior authorization for nasal valve procedures and for implantation of absorbable or nonabsorbable nasal implants. Prior authorization allows review of the clinical indication, prior conservative therapy, and documentation of anatomic findings to support reconstructive (medically necessary) intent.

Prior auth recommended for procedures addressing internal and/or external nasal valve compromise and for placement of implants such as Latera (chunks 2, 32, 11)

Key Definitions and Outcome Measures

Mechanical Nasal Airway Obstruction definition

DefinitionTrouble breathing through the nose due to a bony or cartilaginous deformity

Typical causesNasal valve dysfunction, septal deviation, turbinate hypertrophy, prior nasal trauma or surgery leading to structural compromise

Clinical assessmentRequires correlation of symptoms with physical exam and imaging/photographs documenting deformity consistent with obstruction

Prolonged, Persistent Nasal Airway Obstruction

DefinitionNasal obstruction not responding to six weeks of medical management such as nasal steroids, antihistamines, and decongestants

Exclusions to considerElimination of drug‑induced rhinitis (eg, Rhinitis Medicamentosa) should be confirmed before labeling obstruction as prolonged/persistent

Background and Evidence Context

Background: Mechanical nasal airway obstruction is breathing difficulty caused by bony or cartilaginous deformity. Nasal valve dysfunction (internal and external) and anatomic deformities such as septal deviation, turbinate hypertrophy, rhinophyma, or tip drop can lead to obstructive symptoms. Evaluation typically requires objective and subjective measures (for example, photographic documentation, modified Cottle maneuver, NOSE or rTNSS scores) and consideration of prior medical management; surgical repair is considered reconstructive only when the policy’s specific criteria are met.

Policy Summary

PayerUnitedHealthcare

PolicyRhinoplasty and Other Nasal Procedures

Policy CodePolicy CS107.AE

Change TypeMaterial updates and code removalreferences updated

Effective DateJun 1, 2025

Next Review DateN/A

SourceLink

On This Page

Implants may be considered for patients with dynamic lateral wall collapse when implant use is clinically appropriate, but documentation must show discussion of limited long-term comparative evidence and alternatives (eg, cartilage grafting or open repair); acceptable short- to mid-term symptom improvements have been reported up to 24 months

shared decision making documented

ECRI/Hayes and clinical studies summarize limited-quality evidence

Responder defined as ≥30% reduction in reflective Total Nasal Symptom Score (rTNSS) from baseline

Alternative responder measuresEquivalent meaningful improvement on validated outcomes (eg, NOSE or RQLQ) used in some studies

Use in trialsPrimary endpoint in multiple randomized controlled trials of PNN/SPG and RF neurolysis interventions

rTNSS enrollment thresholds in trials

Common enrollment threshold (some cryoablation RCT)Minimum rTNSS ≥4 (with subscores: rhinorrhea ≥2 and congestion ≥1 used in at least one trial)

Common enrollment threshold (RhinAer/RF trials)rTNSS ≥6 used in multiple trials (eg, Stolovitzky et al., eligibility included rTNSS ≥6)

Additional subscore requirementsTrials often required minimum subscores for rhinorrhea (2–3) and congestion (1–3) depending on study protocol

Prior auth recommended for radiofrequency nasal valve procedures (VivAer, Stylus) and for TCRF treatments (chunks 74, 78, 79)

Prior Authorization

Prior authorization for PNN / implant procedures

Prior authorization is recommended for posterior nasal nerve (PNN) / sphenopalatine ganglion (SPG) ablation procedures (including temperature-controlled RF, cryotherapy, and other device-based neurolytic procedures). Documentation should support symptom severity thresholds and prior medical therapy.

Procedures include TCRF ablation (RhinAer), cryotherapy, and other device-based approaches (chunks 52, 55, 66)
Expect review of rTNSS baseline scores and responder definitions used in trials (chunks 55, 66)

Prior Authorization

Prior authorization: symptom thresholds and prior therapy

Prior authorization decisions will consider symptom thresholds and prior therapy. Many clinical trials and reviews specified minimum symptom scores (e.g., NOSE or rTNSS) and required prior conservative treatment before enrollment.

Common trial thresholds: NOSE Scale ≥ 60 for nasal valve studies (chunk 74); rTNSS ≥ 6 (or ≥ 8) with defined subscore minimums for PNN studies (chunks 55, 64, 66)
Conservative therapy requirements prior to intervention (see next callout) and documentation of failure or intolerance to those therapies (chunks 4, 5, 64)

Documentation Required

Prior authorization: document device indication and anatomy

When requesting prior authorization for device implantation or nasal valve procedures, document the device indication, targeted anatomy (internal nasal valve, external nasal valve, or both), and whether the compromise is static or dynamic. Include planned adjunctive procedures if performed concurrently (e.g., septoplasty, turbinate reduction).

Clearly state whether nasal valve compromise is static or dynamic and which anatomical structures are involved (chunk 2)
If a cartilage graft or specific implant is planned, document the need and role in the surgical plan (chunk 2)
List concurrent nasal procedures scheduled at the same operative setting (chunks 2–4)

Prior Authorization

Prior authorization requirements (UnitedHealthcare processes, InterQual)

UnitedHealthcare prior authorization requirements may incorporate external tools (e.g., InterQual) and plan-specific processes. Providers must submit complete medical records and documentation as requested; failure to provide required records may delay or result in denial.

UnitedHealthcare may use InterQual® criteria to assist in benefit determinations (chunk 95)
Plan-specific prior authorization forms, timelines, and evidence submissions apply — verify requirements with the member's plan (chunk 95)

Denial Risk

Documentation and coding review risk (cosmetic vs reconstructive)

Documentation and coding review risk: failure to clearly demonstrate reconstructive intent, lack of anatomic/functional findings, or use of codes typically billed as cosmetic may trigger additional review or denial. Ensure coding reflects the reconstructive nature when clinical criteria are met.

Codes commonly flagged as cosmetic include many rhinoplasty CPTs; clinical documentation must support functional/reconstructive indication (chunks 10–11)
Include operative details and rationale to support selection of reconstructive CPTs vs cosmetic coding (chunks 2–5)

Denial Risk

Insufficient evidence / justification risk leading to denial

Insufficient evidence or justification in the submitted records may lead to denial. For newer devices and procedures (e.g., absorbable implants, some radiofrequency techniques, and PNN ablation), evidence is evolving and limited in quality; payers may require stronger documentation of benefit and durability.

Absorbable implants (Latera) and some RF treatments have low-to-moderate quality evidence and limited long-term data (chunks 32–34, 36)
If documentation does not demonstrate expected clinical benefit or durability, prior authorization may be denied (chunks 18, 34, 76)

Denial Risk

Documentation insufficiency may lead to denial (prior medical management not documented)

Documentation insufficiency may lead to denial if prior medical management, symptom severity, objective findings, or operative plans are not adequately documented. Prior medical management must be clearly recorded, including dates, duration, and response.

Lack of documented conservative therapy (e.g., ≥4 weeks of appropriate medical therapy where indicated) can be a reason for denial (chunks 4–5)
For chronic rhinitis/PNN procedures, documentation of prior intranasal steroid trial and duration is commonly required (chunk 64)

Documentation Required

Eligibility documentation expectation (trial-like thresholds)

Eligibility documentation expectation: prior authorization submissions should include trial-like data consistent with published studies — baseline and follow-up symptom scores (NOSE, rTNSS), symptom severity class, and responder definitions. Provide objective and patient-reported measures used to justify intervention.

Include baseline NOSE or rTNSS scores and documentation of symptom subscores as applicable (chunks 55, 64, 74, 78)
Define how the patient meets responder thresholds (e.g., ≥20% or ≥30% improvement, or one severity class) used in relevant trials (chunks 74, 78, 66)

Denial Risk

Low quality / limited comparative evidence may trigger denial

Low quality or limited comparative evidence for many implant and some device-based procedures may trigger denials or requests for more information. Payers may require comparative evidence to established surgical techniques (e.g., autologous grafting, open repair) to consider coverage favorable.

Comparative effectiveness versus rhinoplasty or cartilage grafts is often lacking — note limitations in existing studies when submitting authorization requests (chunks 32–37)
Many studies are single-arm, small, or short-duration; provide longer-term follow-up when available (chunks 36, 38, 74)

Denial Risk

Documentation and eligibility risks — failure to provide records may result in denial

Documentation and eligibility risks: failure to provide required medical records, incomplete operative plans, missing photos, or absent objective/subjective measures may cause delays or denials. Submit comprehensive records with the authorization request and respond to follow-up requests promptly.

UnitedHealthcare may request full medical records to confirm clinical criteria — incomplete records risk denial (chunks 7, 95)
Plan-specific requirements, state variations, and prior authorization forms must be followed (chunk 94)

Documentation Required

Required clinical documentation

Required clinical documentation to support medical necessity includes both objective and subjective assessments, photographic documentation, and a clear operative plan. For nasal valve repair and related reconstructive procedures, UnitedHealthcare expects documentation similar to criteria used in clinical studies and in the policy Instructions for Use.

Photos clearly documenting dynamic collapse or anatomic narrowing consistent with clinical exam (chunks 2, 3)
Modified Cottle maneuver demonstration with subjective and audible improvement documented (chunk 2)
Surgeon description of static vs dynamic compromise, involvement of internal and/or external nasal valve, and clear surgical plan including need for graft or implant (chunk 2)
Baseline NOSE or rTNSS scores and other relevant patient-reported outcome measures with dates (chunks 74, 78, 55)

Documentation Required

Suggested documentation to support medical necessity (trial‑like data)

Suggested documentation to support medical necessity: when available, provide trial-like data demonstrating prior improvement attempts and response over time, serial symptom scores, and documentation of why less invasive alternatives were insufficient or inappropriate.

Serial NOSE/rTNSS scores showing persistent significant symptoms despite conservative therapy (chunks 74, 55, 64)
Documentation of prior therapies tried and failed (e.g., intranasal steroids, immunotherapy, medical management), including duration and dates (chunks 4, 64)
If available, objective measures (endoscopic findings, lateral wall motion video, LWI scores) to supplement subjective reporting (chunks 38, 37)

Note

Consider alternatives before implants

Consider alternatives before implants and device-based procedures. Where appropriate, surgical cartilage grafting, open repair techniques, or continued medical management may be reasonable alternatives and should be documented in the decision-making rationale.

Document why autologous grafting or open repair is not appropriate or has previously failed if an implant is being proposed (chunks 36, 32)
If implant is selected to avoid more invasive surgery, include discussion of risks, benefits, and expected durability (chunks 32–34)

Step Therapy

Conservative therapy required before intervention

Conservative therapy is required before many reconstructive nasal interventions. For rhinoplasty-related functional procedures and PNN interventions, document prior appropriate conservative measures and their duration (commonly ≥4 weeks where indicated) and the patient's inadequate response.

For rhinoplasty and many valve repairs, obstructive symptoms should persist despite conservative management for 4 weeks or greater, including nasal steroids or immunotherapy when appropriate (chunks 4–5)
For PNN procedures, trials often required ≥4 weeks of intranasal steroids and documented inadequate response (chunk 64)

Note

Not specified

Not specified in this section of the policy.

Implication for surgeryProlonged/persistent designation supports consideration of surgical intervention when other criteria are met

External Nasal Valve definition

DefinitionExternal Nasal Valve: anatomical structures including caudal septum, lower lateral cartilage, alar rim, and nostril sill that contribute to external valve function

Clinical relevanceCompromise of these structures can produce dynamic or static lateral wall collapse contributing to nasal airway obstruction

AssessmentExam maneuvers (eg, modified Cottle) and photographic/video documentation often used to demonstrate external valve dysfunction

Rhinoplasty definition

DefinitionRhinoplasty: a surgical procedure that alters the shape or appearance of the nose while preserving or enhancing the nasal airway; may be performed for aesthetic and/or functional indications and can include adjunctive septal, valve, turbinate, or sinus procedures

IndicationsPerformed for reconstructive reasons to improve nasal deformity or restore nasal physiological function, or for cosmetic purposes

Adjunctive proceduresWhen adjunctive septal/turbinate/valve procedures do not affect nasal shape, they may be excluded from a rhinoplasty definition in some guidelines

Absorbable nasal cartilage support implant (e.g., Latera) definition

DefinitionAbsorbable nasal cartilage support implant (eg, Latera): a polylactic acid bioabsorbable implant placed submucosally to provide lateral wall support, intended to absorb over ~2 years leaving a collagen track to support the nasal valve

MechanismAnchors above the maxilla to provide cantilever support to upper and lower lateral cartilages, intended to reduce nasal valve collapse and improve airflow

Regulatory/availability noteLatera (Stryker) is identified in the policy as the only FDA‑cleared absorbable nasal implant at the time referenced

Absorbable nasal cartilage support implant (alternate reference)

Alternate reference — device and evidence contextLatera bioabsorbable implant: in‑office and multicenter studies report short‑term (3–12 month) improvements in NOSE and VAS scores for dynamic nasal valve collapse; longer‑term comparative data are limited

Study limitationsMany studies lacked active comparison groups and had heterogeneous concomitant procedures; longer follow‑up needed beyond 12–24 months

Clinical use implicationImplants are considered an option for selected patients with dynamic lateral wall collapse but require documentation of alternatives and informed discussion of limited long‑term evidence

TCRF for NSB reduction (VivAer) definition

DefinitionTemperature‑controlled radiofrequency (TCRF) treatment (VivAer) for nasal septal swell body (NSB) reduction: device‑delivered thermal energy to reduce NSB tissue size to improve nasal airway obstruction

Reported outcomesProspective studies report significant NOSE score improvements through 12 months; randomized and cohort data cited for durability up to 24 months in some reports

Evidence limitationsStudies are generally small, single‑arm or open‑label; randomized data are limited and longer‑term randomized comparisons are needed

PNN/SPG ablation definition

DefinitionPNN/SPG ablation: targeted ablation (eg, cryoablation or temperature‑controlled RF neurolysis) of the posterior nasal nerve or sphenopalatine ganglion region to reduce symptoms of chronic rhinitis

Typical eligibility in trialsAdults with chronic rhinitis ≥6 months duration and inadequate response to prior medical therapy (eg, intranasal steroids ≥4 weeks)

Outcomes reportedRCTs and follow‑ups report clinically meaningful reductions in rTNSS and sustained responder rates to 12–24 months in many participants, though medication management varied

rTNSS definition

DefinitionrTNSS (reflective Total Nasal Symptom Score): a validated patient‑reported measure quantifying nasal symptom severity used in chronic rhinitis trials

ComponentsIncludes subscores for rhinorrhea, nasal congestion, sneezing, and nasal itching (often used as eligibility and outcome measure)

Use in trialsEmployed as primary outcome in RCTs of PNN/SPG ablation and cryoablation with predefined thresholds for enrollment and responder definitions

NOSE definition

DefinitionNOSE (Nasal Obstruction Symptom Evaluation): a patient‑reported outcome measuring severity of nasal obstruction used in nasal valve dysfunction studies

Responder criteria exampleUsed to define responder status in TCRF trials (eg, ≥20% reduction in NOSE score or ≥1 clinical severity class improvement)

Clinical applicationCommonly used to document baseline severity and postprocedure benefit for nasal valve and NSB interventions

Responder (in TCRF RCT and other studies) definition

Responder definition (TCRF and some RF trials)Responder defined as ≥20% reduction in NOSE Scale score or ≥1 clinical severity class improvement from baseline (used as primary endpoint in Silvers RCT)

Alternative responder thresholdsOther studies report responder as ≥30% rTNSS reduction for chronic rhinitis interventions (different metric)

Use in follow-up studiesResponder rates reported at 3 months and sustained to 12–24 months in several TCRF and RF cohorts

VivAer Stylus (device) definition/clearance

Device/clearanceVivAer Stylus: temperature‑controlled radiofrequency (TCRF) device that received FDA 510(k) clearance in March 2020 for coagulation/shrinkage of submucosal tissue in the internal nasal valve to treat nasal airway obstruction

Intended useCoagulation/shrinkage of submucosal tissue including cartilage in internal nasal valve area to reduce NAO

Regulatory noteFDA clearance is informational and not by itself a coverage determinant per policy language

TC-RF (term)

Term expansionTC‑RF / TCRF: Temperature‑controlled radiofrequency treatment — energy‑based submucosal tissue remodeling used in nasal valve and NSB procedures

Clinical applicationsUsed for nasal valve remodeling (VivAer) and posterior nasal nerve/RF neurolysis procedures in studies cited

Evidence contextRCTs and observational studies cited in policy evaluated TC‑RF/TCRF for safety and efficacy across nasal indications

Bioabsorbable nasal implant (term)

TermBioabsorbable nasal implant: a polylactic acid (PLA) bioabsorbable implant placed to support lateral nasal wall/cartilage and intended to absorb over time leaving collagen support

Example productLatera (manufacturer: Stryker) referenced as the commercially available absorbable nasal implant in the policy

Clinical evidence noteShort‑ to mid‑term symptom improvements reported (eg, up to 12–24 months in some series) but longer‑term comparative data are limited